(52) conducted a systematic review to explore the effects of ezetimibe in the treatment of patients with NAFLD/NASH, and the results suggested that ezetimibe may impact liver steatosis, hepatocellular ballooning and ALT levels, which yielded different results with this study. The gene discussed is GPT; the disease is fatty liver disease.